GSK Reports Promising Early Results for Ovarian and Womb Cancer Drug Mo-Rez
Pharmaceutical giant GSK has announced positive early-stage trial results for Mocertatug Rezetecan, known as Mo-Rez, a new treatment for gynaecological cancers. The antibody-drug conjugate, acquired from China’s Hansoh Pharma, demonstrated significant efficacy by shrinking or eliminating tumours in 62% of patients with chemotherapy-resistant ovarian cancer and 67% of those with endometrial cancer. With a manageable safety profile where few patients discontinued due to side effects, GSK plans to advance directly to late-stage trials globally. This development is a strategic milestone for CEO Luke Miels, who aims to accelerate drug development and bolster GSK’s oncology portfolio. Analysts project Mo-Rez could become a blockbuster drug with peak annual sales exceeding £2 billion, contributing significantly to the company’s £40 billion sales target for 2031. The announcement underscores GSK’s renewed focus on oncology following its re-entry into the sector less than a decade ago, aiming to compete more effectively with rivals like AstraZeneca.
Wire timeline
GSK Reports Promising Early Results for Ovarian and Womb Cancer Drug Mo-Rez
Pharmaceutical giant GSK has announced positive early-stage trial results for Mocertatug Rezetecan, known as Mo-Rez, a new treatment for gynaecological cancers. The antibody-drug conjugate, acquired from China’s Hansoh Pharma, demonstrated significant efficacy by shrinking or eliminating tumours in 62% of patients with chemotherapy-resistant ovarian cancer and 67% of those with endometrial cancer. With a manageable safety profile where few patients discontinued due to side effects, GSK plans to advance directly to late-stage trials globally. This development is a strategic milestone for CEO Luke Miels, who aims to accelerate drug development and bolster GSK’s oncology portfolio. Analysts project Mo-Rez could become a blockbuster drug with peak annual sales exceeding £2 billion, contributing significantly to the company’s £40 billion sales target for 2031. The announcement underscores GSK’s renewed focus on oncology following its re-entry into the sector less than a decade ago, aiming to compete more effectively with rivals like AstraZeneca.
The Guardian